Arabi, Y., Gordon, A., Derde, L., Nichol, A., Murthy, S., Al-Beidh, F., Annane, D., Al-Swaidan, L., Beane, A., Beasley, R., Berry, L., Bhimani, Z., Bonten, M., Bradbury, C., Brunkhorst, F., Buxton, M., Buzgau, A., Cheng, A., de Jong, M., Detry, M., Duffy, E., Estcourt, L., Fitzgerald, M., Fowler, R., Girard, T., Goligher, E., Goossens, H., Haniffa, R., Higgins, A., Hills, T., Horvat, C., Huang, D., King, A., Lamontagne, F., Lawler, P., Lewis, R., Linstrum, K., Litton, E., Lorenzi, E., Malakouti, S., McAuley, D., McGlothlin, A., Mcguinness, S., McVerry, B., Montgomery, S., Morpeth, S., Mouncey, P., Orr, K., Parke, R., Parker, J., Patanwala, A., Rowan, K., Santos, M., Saunders, C., Seymour, C., Shankar-Hari, M., Tong, S., Turgeon, A., Turner, A., Van de Veerdonk, F., Zarychanski, R., Green, C., Berry, S., Marshall, J., McArthur, C., Angus, D., Webb, S. & REMAP-CAP Investigators 2021, 'Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial', Intensive Care Medicine, 47 (8 ), pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5